Morris v. Zelch (In Re Regional Diagnostics, LLC.)

372 B.R. 3, 2007 Bankr. LEXIS 1825, 48 Bankr. Ct. Dec. (CRR) 99, 2007 WL 1587256
CourtUnited States Bankruptcy Court, N.D. Ohio
DecidedJune 1, 2007
Docket19-10705
StatusPublished
Cited by10 cases

This text of 372 B.R. 3 (Morris v. Zelch (In Re Regional Diagnostics, LLC.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Morris v. Zelch (In Re Regional Diagnostics, LLC.), 372 B.R. 3, 2007 Bankr. LEXIS 1825, 48 Bankr. Ct. Dec. (CRR) 99, 2007 WL 1587256 (Ohio 2007).

Opinion

MEMORANDUM OF OPINION

PAT E. MORGENSTERN-CLARREN, Bankruptcy Judge.

In this action, the chapter 11 creditors’ trustee seeks to recover funds from multiple defendants following confirmation of the debtors’ plan of reorganization. 1 Two sets of defendants bring separate motions to dismiss. 2 For the reasons stated below, both motions are denied, and the plaintiff is ordered to amend count I of the complaint to comply with federal rule of civil procedure 9 (made applicable by federal rule of bankruptcy procedure 7009).

*7 JURISDICTION

Jurisdiction exists under 28 U.S.C. § 1334 and General Order No. 84 entered by the United States District Court for the Northern District of Ohio. At this point in the proceedings, it is unnecessary to distinguish between core and non-core claims. See Thickstun Bros. Equip. Co., Inc. v. Encompass Servs. Corp. (In re Thickstun Bros. Equip. Co., Inc.), 344 B.R. 515, 520 (6th Cir. BAP 2006) (noting that it is only-necessary to determine whether the matter is “related to” the bankruptcy to decide whether the matter is within the bankruptcy court’s jurisdiction). The court finds that counts I, II, IV, V, VI, and VII are at least related to the bankruptcy, as the successful or unsuccessful adjudication of those claims (either before or after confirmation) could have altered the debtors’ rights, liabilities, or options, and thereby impacted the handling and administration of the bankrupt estate. See Lindsey v. O’Brien, Tanski, Tanzer & Young Health Care Providers of Conn. (In re Dow Corning Corp.), 86 F.3d 482, 489 (6th Cir.1996). Of the seven counts in the complaint, the parties only dispute the court’s jurisdiction over count III. As discussed below in connection with the motion to dismiss brought by Mark A. Abbott, Barry J. Uphoff, and Robert W. Koehn, the court finds that it has jurisdiction over that claim.

FACTS

Procedural History

Regional Diagnostics L.L.C. (RDI), Regional Diagnostics Holdings, L.L.C. (RDH), and TR Radiology, Inc. (TRR) (collectively, the debtors) filed voluntary chapter 11 petitions on April 20, 2005. 3 On February 8, 2006, the court approved the debtors’ Second Amended Disclosure Statement (the disclosure statement). 4 Then, on April 7, 2006, the court entered an order (the confirmation order) 5 confirming The Second Amended Joint Plan of Liquidation (the plan). 6 Pursuant to the confirmation order, plaintiff Robert A. Morris was appointed as creditors’ trustee.

Following confirmation, the plaintiff filed a complaint against James V. Zelch, M.D., Mark Zelch, Nancy Lynn Westrich, M.D., Regional Health Services, Inc. (RHS), JVZ Partners Limited (JVZ), and JZ Investment Corp. (JZ) (collectively, the Zelch Defendants), and Mark A. Abbott, Barry J. Uphoff, and Robert W. Koehn (collectively, the Trivest Manager Defendants). 7 The complaint states these seven causes of action:

(1) Fraudulent Transfers Based Upon Actual Fraud (Count I) against all of the Zelch Defendants;
(2) Fraudulent Transfers Based Upon Constructive Fraud (Count II) against all of the Zelch Defendants;
(3) Breach of Fiduciary Duty (Count III) against Dr. Zelch, Mark Zelch, and the Trivest Manager Defendants;
(4) Unjust Enrichment (Count IV) against all of the Zelch Defendants;
(5) Conversion (Count V) against Dr. Zelch and Mark Zelch;
*8 (6) Equitable Subordination of Seller Entities’ Claims (Count VI) against RHS, JVZ, and JZ; and
(7) Objection to Claim of Seller Entities Pursuant to 11 U.S.C. § 502 (Count VII) against RHS, JVZ, and JZ. 8

In response, the Zelch Defendants and the Trivest Manager Defendants filed separate motions to dismiss. The Zelch Defendants request dismissal under federal rules of civil procedure 9, 12, and 19 (made applicable by federal rules of bankruptcy procedure 7009, 7012, and 7019) and the principle of res judicata. 9 The Trivest Manager Defendants move to dismiss under federal rules of civil procedure 12(b)(1) and (6) (made applicable by federal rule of bankruptcy procedure 7012(b)). 10 The parties filed briefs in support of and in opposition to these motions. 11

Factual Allegations in the Complaint

The factual allegations that underlie the complaint center around a leveraged buyout (LBO) of Dr. Zelch’s company, RDI. 12 Dr. Zelch founded RDI, a medical services company that performed MRIs, CT scans, ultrasounds, X-rays, and other services. 13 Dr. Zelch and his family owned RDI until March of 2003, when they sold a 60% interest in the company to Trivest Partners, L.P. for approximately $52.5 million ($42.5 million in cash and $10 million in the form of a seller’s note). 14 To finance this purchase, RDI obtained approximately $26 million in senior secured loans from Merrill Lynch and Royal Bank of Canada. 15 RDI obtained an additional $13.5 million in senior subordinated loans from Gleacher Mezzanine and Banc Boston Investments, Inc. 16 These additional loans took the form of so-called “mezzanine financing,” a hybrid of debt and equity financing. 17

The plaintiff alleges that this arrangement amounted to wrongdoing on the part of the defendants because, at the time of the sale, RDI was grossly overvalued. 18 According to the plaintiff, the large shareholder payments were justified by an initial value of RDI at approximately $73.2 million. 19 The parties to the sale negotiated a price based on a complex formula using RDI’s 2002 earnings before interest, tax, depreciation and amortization (EBIT-DA) as a significant variable. 20 Because of the EBITDA’s importance, the parties to the sale retained the accounting firm of Crowe Chizek and Company LLC to calculate RDI’s EBITDA for 2002. 21

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
372 B.R. 3, 2007 Bankr. LEXIS 1825, 48 Bankr. Ct. Dec. (CRR) 99, 2007 WL 1587256, Counsel Stack Legal Research, https://law.counselstack.com/opinion/morris-v-zelch-in-re-regional-diagnostics-llc-ohnb-2007.